

FAGSEMINAR

Somatoforme lidelser

Mandag 9.oktober 2017

LITTERATURLISTE

Anbefalt lest før kurset:

Malt UF, Boye B, Malt EA. **Psykosomatiske lidelser**. I Malt UF, Andreassen OA, Melle I, Årslund D, red. *Lærebok i psykiatri*. Oslo Gyldendal akademiske 2014, 515-560 (Kapittel 18).

van den Bergh O, Witthöft M, Petersen S, Brown RJ. **Symptoms and the body: Taking the inferential leap**. *Neurosci Biobehav Rev*. 2017 Mar;74(Pt A):185-203.

Löwe B, Piontek K, Daubmann A, Härter M, Wegscheider K, König HH, Shedden-Mora M. **Effectiveness of a stepped, collaborative, and coordinated health care network for somatoform disorders** (Sofu-Net): A controlled cluster cohort study. *Psychosom Med*. 2017 May 12. doi: 10.1097/PSY.0000000000000491. [Epub ahead of print]

Supplerende litteratur for fordypning i spesielle emner:

SOMATOFORME LIDELSER GENERELT (ICD-10 F45.0 og F45.1)

Agger JL, Schröder A, Gormsen LK, Jensen JS, Jensen TS, Fink PK. **Imipramine versus placebo for multiple functional somatic syndromes** (STreSS-3): a double-blind, randomised study. *Lancet Psychiatry*. 2017 May;4(5):378-388

Chowdhury S, Burton C. **Associations of treatment effects** between follow-up times and between outcome domains in interventions for somatoform disorders: Review of three Cochrane reviews. *J Psychosom Res*. 2017 Jul; 98:10-18

Eikelboom EM, et al. A systematic review and meta-analysis of the **percentage of revised diagnoses in functional somatic symptoms**. *J Psychosom Res* 2016; 88: 60-67.

Heinbokel C, Lehmann M, Pohontsch NJ, Zimmermann T, Althaus A, Scherer M, Löwe B. **Diagnostic barriers** for somatic symptom disorders in primary care: study protocol for a mixed methods study in Germany. *BMJ Open*. 2017 Aug 11;7(8):e014157. doi: 10.1136/bmjopen-2016-014157.

Kohlmann S, Gierk B, Hilbert A, Brähler E, Löwe B. The **overlap of somatic, anxious and depressive syndromes**: A population-based analysis. *J Psychosom Res*. 2016 Nov;90:51-56

Murray AM, Toussaint A, Althaus A, Löwe B. The **challenge of diagnosing non-specific, functional, and somatoform disorders**: A systematic review of barriers to diagnosis in primary care. *J Psychosom Res*. 2016 Jan;80:1-10

Rask MT, Ørnboel E, Rosendal M, Fink P. Long-Term Outcome of Bodily Distress Syndrome in Primary Care: A **Follow-Up Study on Health Care Costs, Work Disability, and Self-Rated Health**. Psychosom Med. 2017 Apr;79(3):345-357.

Rief W, Burton C, Frostholm L, Henningsen P, Kleinstäuber M, Kop WJ, Löwe B, Martin A, Malt U, Rosmalen J, Schröder A, Shedden-Mora M, Toussaint A, van der Feltz-Cornelis C. **Core Outcome Domains** for Clinical Trials on Somatic Symptom Disorder, Bodily Distress Disorder and Functional Somatic Syndromes: EURONET-SOMA Recommendations. Psychosom Med. 2017 Jul 7. doi: 10.1097/PSY.0000000000000502. [Epub ahead of print]

Rosendal M, Blankenstein AH, Morriss R, Fink P, Sharpe M, Burton C. **Enhanced care by generalists for functional somatic symptoms and disorders in primary care**. Cochrane Database Syst Rev. 2013 Oct 18;(10):CD008142. doi: 10.1002/14651858.CD008142.pub2

Schröder A, Ørnboel E, Jensen JS, Sharpe M, Fink P. **Long-term economic evaluation** of cognitive-behavioural group treatment versus enhanced usual care for functional somatic syndromes. J Psychosom Res. 2017 Mar; 94:73-81

HYPOKONDRI (HELSEANGST) (ICD-10 F45.2)

Sanatinia R, Wang D, Tyrer P, Tyrer H, Crawford M, Cooper S, Loebenberg G, Barrett B. **Impact of personality status** on the outcomes and cost of **cognitive-behavioural** therapy for health anxiety. Br J Psychiatry. 2016 Sep;209(3):244-50

Tyrer P, Cooper S, Salkovskis P, et al. **Clinical and cost-effectiveness of cognitive behaviour therapy** for health anxiety in medical patients: a multicentre randomized controlled trial. Lancet 2014; 383:219-25.

Wilhelmsen I. **Hypokondri og kognitiv terapi**. Oslo: Pax forlag 2014.

Krebs G, Fernández de la Cruz L, Mataix-Cols D. Recent advances in understanding and **managing body dysmorphic disorder**. Evid Based Ment Health. 2017 Jul 20. pii: ebmental-2017-102702. doi: 10.1136/eb-2017-102702. [Epub ahead of print]

SOMATIFORM AUTONOM DYSFUNKSJON (ICD-10 F45.3x)

Bringager CB, Dammen T, Friis S. **Nonfearful panic disorder in chest pain patients**. Psychosomatics. 2004 Jan-Feb;45(1):69-79. [ICD-10 F41.0 & F45.30]

Bringager CB, Friis S, Arnesen H, Dammen T. **Nine-year follow-up of panic disorder in chest pain patients**: clinical course and predictors of outcome. Gen Hosp Psychiatry. 2008 Mar-Apr;30(2):138-46. [ICD-10 F41.0 & F45.30]

Tully PJ, Turnbull DA, Beltrame J, Horowitz J, Cosh S, Baumeister H, Wittert GA. **Panic disorder and incident coronary heart disease**: a systematic review and meta-regression in 1131612 persons and 58111 cardiac events. Psychol Med. 2015 Oct;45(14):2909-20. [ICD-10 F41.0 & F45.30].

Bredenoord AJ. Management of **belching, hiccups, and aerophagia**. Clin Gastroenterol Hepatol. 2013 Jan;11(1):6-12. [F45.31]

Eriksson EM, Andrén KI, Kurlberg GK, Eriksson HT. Aspects of the **non-pharmacological treatment of irritable bowel syndrome**. World J Gastroenterol. 2015 Oct 28;21(40):11439-49. [F45.32]

Löwe B, Lohse A, Andresen V, Vettorazzi E, Rose M, Broicher W. The **Development of Irritable Bowel Syndrome**: A Prospective Community-Based Cohort Study. Am J Gastroenterol. 2016 Sep;111(9):1320-9. [F45.32]

Jones M, Harvey A, Marston L, O'Connell NE. Breathing exercises for **dysfunctional breathing/hyperventilation syndrome** in adults. Cochrane Database Syst Rev. 2013 May 31;(5):CD009041. doi: 10.1002/14651858.CD009041.pub2 [F45.33]

Hibbing ME, Conover MS, Hultgren SJ. The unexplored relationship between **urinary tract** infections and the autonomic nervous system. Auton Neurosci. 2016 Oct;200:29-34. [F45.34]

Bakke A, Malt UF. Psychological predictors of symptoms of **urinary tract** infection and bacteriuria in patients treated with clean intermittent catheterization: a prospective 7-year study. Eur Urol. 1998;34(1):30-6. [F45.34]

Khan FU, Ihsan AU, Khan HU, Jana R, Wazir J, Khongorzul P, Waqar M, Zhou X. Comprehensive overview of **prostatitis**. Biomed Pharmacother. 2017 Aug 12;94:1064-1076 [F45.34]

MEDISINSK UFORKLARLIGE SYMPTOMER (ICD-10 koder varierer)

Rosendal M, Olde Hartman TC, Aamland A, van der Horst H, Lucassen P, Budtz-Lilly A, Burton C. "**Medically unexplained**" symptoms and symptom disorders in primary care: prognosis-based recognition and classification. BMC Fam Pract. 2017 Feb 7;18(1):18. doi: 10.1186/s12875-017-0592-6.

Geraghty K, Hann M, Kurtev S. **Myalgic encephalomyelitis/chronic fatigue syndrome** patients' reports of symptom changes following cognitive behavioural therapy, graded exercise therapy and pacing treatments: Analysis of a primary survey compared with secondary surveys. J Health Psychol. 2017 Aug 1:1359105317726152. doi: 10.1177/1359105317726152. [Epub ahead of print]

Larun L, Brurberg KG, Odgaard-Jensen J, Price JR. Exercise therapy for **chronic fatigue syndrome**. Cochrane Database Syst Rev. 2017 Apr 25;4:CD003200. doi: 10.1002/14651858.CD003200.pub7. Review.

Owe JF, Næss H, Gjerde IO, Bødtker JE, Tysnes OB. Utredning ved mistenkt **kronisk utmattelsessyndrom/myalgisk encefalopati**. Tidsskr Nor Laegeforen. 2016 Feb 9;136(3):227-32.

Adler-Neal AL, Zeidan F. Mindfulness Meditation for **Fibromyalgia**: Mechanistic and Clinical Considerations. *Curr Rheumatol Rep*. 2017 Sep;19(9):59. doi: 10.1007/s11926-017-0686-0

Kia S, Choy E. Update on Treatment Guideline in **Fibromyalgia** Syndrome with Focus on Pharmacology. *Biomedicines*. 2017 May 8;5(2). pii: E20. doi: 10.3390/biomedicines5020020

Schmidt-Wilcke T, Diers M. New Insights into the Pathophysiology and Treatment of **Fibromyalgia**. *Biomedicines*. 2017 May 13;5(2). pii: E22. doi: 10.3390/biomedicines5020022

SMERTE (ICD-10 kode F45.4)

Chou R, Deyo R, Friedly J, Skelly A, Hashimoto R, Weimer M, Fu R, Dana T, Kraegel P, Griffin J, Grusing S, Brodt ED. **Nonpharmacologic Therapies for low back pain**: A Systematic Review for an American College of Physicians Clinical Practice Guideline. *Ann Intern Med*. 2017 Apr 4;166(7):493-505

Chou R, Deyo R, Friedly J, Skelly A, Weimer M, Fu R, Dana T, Kraegel P, Griffin J, Grusing S. Systemic **Pharmacologic Therapies for low back pain**: A Systematic Review for an American College of Physicians Clinical Practice Guideline. *Ann Intern Med*. 2017 Apr 4;166(7):480-49

Fors EA, Stiles T, red. **Smertepsykologi**. Oslo: Universitetsforlaget, 2017.

Kirste U, et al. **Kroniske bekkensmerter**. Veileder i gynekologi 2015. Oslo: Norsk gynekologisk forening.

Brünahl C, Dybowski C, Albrecht R, Riegel B, Höink J, Fisch M, Löwe B. Mental disorders in patients with **chronic pelvic pain** syndrome (CPPS). *J Psychosom Res*. 2017 Jul;98:19-26.

Haugstad GK, Haugstad TS, Kirste UM, Leganger S, Klemmetsen I, Malt UF. Mensendieck somatocognitive therapy as treatment approach to **chronic pelvic pain**: results of a randomized controlled intervention study. *Am J Obstet Gynecol*. 2006 May;194(5):1303-10.

PLACEBO

Flaten MA. **Pain-Related Negative Emotions and Placebo Analgesia**. I, Benedetti F, et al, red. *Placebo. A handbook*. I Berlin Heidelberg: Springer-Verlag Berlin Heidelberg 2014, 81-95.